AngioDynamics, Inc. officer Stephen Trowbridge filed a Form 144 notice on October 29, 2026, disclosing a proposed sale of 23,615 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services.

Key Highlights

  • Proposed sale: Stephen Trowbridge, an officer of AngioDynamics, Inc., proposes to sell 23,615 shares of common stock with an aggregate market value of $289,722.00.
  • Exchange and outstanding shares: The securities are listed on NASDAQ; AngioDynamics reported 42,054,450 shares of common stock outstanding at the time of the notice.
  • Approximate sale date: The proposed sale is dated October 29, 2026, and is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.
  • Prior sales in past 3 months: Trowbridge sold 1,720 shares of common stock on October 28, 2026, for gross proceeds of $20,929.09.
  • Acquisition history: The shares to be sold were acquired via restricted stock grants, Employee Stock Purchase Plan purchases, and performance shares from the issuer, with acquisition dates ranging from August 3, 2015 to July 11, 2016, according to the filing.

AngioDynamics Officer Files Rule 144 Notice for Proposed Common Stock Sale

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Stephen Trowbridge, identified as an officer of AngioDynamics, Inc. (NASDAQ:ANGO), has provided notice of a proposed sale of 23,615 shares of AngioDynamics common stock. The filing lists an aggregate market value of $289,722.00 for the proposed sale. The approximate date of the sale is stated as October 29, 2026, with Morgan Stanley Smith Barney LLC Executive Financial Services serving as the named broker.

The filing discloses that the securities to be sold were acquired through three types of transactions: restricted stock grants from the issuer acquired on August 3, 2015 (10,605 shares); Employee Stock Purchase Plan shares acquired on August 31, 2015 (10,132 shares); and performance shares acquired on July 11, 2016 (2,878 shares). The filing's remarks section states that "the securities to be sold were acquired upon the vesting of restricted stock during the period of 08/03/2015 through 07/21/2025" and "upon the purchase of Employee Stock Purchase Plan shares during the period of 08/31/2015 through 08/31/2025."

In the three months prior to this notice, Trowbridge reported one prior sale: 1,720 shares of AngioDynamics common stock sold on October 28, 2026, generating gross proceeds of $20,929.09, according to the filing. AngioDynamics, Inc. is headquartered at 14 Plaza Drive, Latham, New York 12110, and carries SEC file number 000-50761.

What Was Disclosed

A Form 144 notice was filed on October 29, 2026, by AngioDynamics officer Stephen Trowbridge, indicating a proposed sale of 23,615 shares of common stock valued at $289,722.00, with one prior sale of 1,720 shares reported in the preceding three months.